FDA Approves ImageChecker Computer System

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 8
Volume 7
Issue 8

ROCKVILLE, Md--The FDA has approved a new computer system, the M1000 ImageChecker, made by R2 Technology, Inc., Los Altos, California, to aid radiologists in reviewing mammograms. Studies show that use of the device improved the radiologists’ detection rate from approximately 80 out of 100 cancers to almost 88 out of 100.

ROCKVILLE, Md--The FDA has approved a new computer system, the M1000 ImageChecker, made by R2 Technology, Inc., Los Altos, California, to aid radiologists in reviewing mammograms. Studies show that use of the device improved the radiologists’ detection rate from approximately 80 out of 100 cancers to almost 88 out of 100.

ImageChecker uses a laser beam to convert the mammographic image into a digital signal. The signal is processed in a high-speed computer to identify suspicious areas, which are then highlighted with markers on a video display of the mammographic image. The radiologist, who has already reviewed the mammo-gram in the conventional manner, then looks at the suspicious areas highlighted by ImageChecker and reviews those same areas on the original mammogram to see if any escaped notice, and, if so, whether they require further evaluation.

FDA’s approval of ImageChecker was based on data from clinical studies and the recommendation of the Radiological Devices Panel of FDA’s Medical Devices Advisory Committee.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content